HighTower Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

HighTower Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-8,375	Closed	-$207K	–	2552
2019 Q1	$207K	Buy	+8,375	New	+$210K	﹤0.01%	1941
2018 Q4	–	Sell	-8,845	Closed	-$263K	–	2411
2018 Q3	$263K	Sell	8,845 -2,025	-19%	-$78.4K	﹤0.01%	1796
2018 Q2	$495K	Buy	10,870 +6,673	+159%	+$325K	﹤0.01%	1455
2018 Q1	$222K	Buy	+4,197	New	+$245K	﹤0.01%	1827
2017 Q4	–	Sell	-2,391	Closed	-$195K	–	2412
2017 Q3	$195K	Sell	2,391 -1,538	-39%	-$122K	﹤0.01%	1921
2017 Q2	$367K	Buy	+3,929	New	+$240K	﹤0.01%	1519
2016 Q4	–	Sell	-16,625	Closed	-$598K	–	2069
2016 Q3	$598K	Buy	+16,625	New	+$357K	0.01%	1147
2016 Q2	–	Sell	-10,425	Closed	-$199K	–	2078
2016 Q1	$199K	Buy	10,425 +2,125	+26%	+$45K	﹤0.01%	1811
2015 Q4	$292K	Buy	8,300 +3,793	+84%	+$245K	﹤0.01%	1584
2015 Q3	$415K	Buy	4,507 +1,100	+32%	+$95.2K	0.01%	1293
2015 Q2	$300K	Buy	+3,407	New	+$292K	﹤0.01%	1195

Other funds holding CLVS

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

HighTower Advisors's CLVS Position: Q2 2019 in Review

HighTower Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 8,375 shares — an estimated $207K sold.

HighTower Advisors first reported a position in CLVS in Q2 2015 and held it in 11 quarters. The position peaked at $598K in Q3 2016. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

HighTower Advisors reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
HighTower Advisors sold 8,375 Clovis Oncology, Inc. shares in Q2 2019, an estimated $207K.
HighTower Advisors first reported a position in Clovis Oncology, Inc. in Q2 2015 and held it in 11 quarters.
HighTower Advisors's Clovis Oncology, Inc. position peaked at $598K in Q3 2016.
167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on HighTower Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.